Genotoxic effects of the antileishmanial drug glucantime^®SOUSA LIMA, Mayara Ingrid; ARRUDA, Viviane Oliveira; CARNEIRO ALVES, Eliza Vanessa et al.Archives of toxicology. 2010, Vol 84, Num 3, pp 227-232, issn 0340-5761, 6 p.Article

Oral delivery of meglumine antimoniate-β-cyclodextrin complex for treatment of leishmaniasisDEMICHELI, Cynthia; OCHOA, Rosemary; DA SILVA, José B. B et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 1, pp 100-103, issn 0066-4804, 4 p.Article

Glucantime-resistant Leishmania tropica isolated from iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugsHADIGHI, R; BOUCHER, P; KHAMESIPOUR, A et al.Parasitology research (1987). 2007, Vol 101, Num 5, pp 1319-1322, issn 0932-0113, 4 p.Article

Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (glucantime®) alone for the treatment of cutaneous leishmaniasisASILIAN, A; SADEGHINIA, A; FAGHIHI, G et al.International journal of dermatology. 2004, Vol 43, Num 4, pp 281-283, issn 0011-9059, 3 p.Article

Traitement de la leishmaniose cutanée par cryothérapie associée ou non au Glucantime® intralésionnel = Cryotherapy with or without intralesional antimony in the treatment of cutaneous leishmaniasisCHAABANE, H; MASMOUDI, A; DAMMAK, A et al.Annales de dermatologie et de vénéréologie. 2009, Vol 136, Num 3, pp 278-279, issn 0151-9638, 2 p.Article

Traitement par amphotéricine B liposomale d'une leishmaniose cutanée contractée à Djibouti et résistante à l'antimoniate de méglumine = Successful treatment of meglumine-antimoniate resistant cutaneous leishmaniasis acquired in Djibouti with AmBisome®RAPP, C; IMBERT, P; DARIE, H et al.Bulletin de la Société de pathologie exotique. 2003, Vol 96, Num 3, pp 209-211, issn 0037-9085, 3 p.Conference Paper

Monitoring drug resistance in leishmaniasisCROFT, Simon L.TM & IH. Tropical medicine & international health. 2001, Vol 6, Num 11, pp 899-905, issn 1360-2276Conference Paper

Efficacité du traitement de la leishmaniose cutanée zoonotique par le glucantime en intra-lésionnel. Dans les conditions des soins de santé de base = Efficacy of intr-lesionnel glucantine as a treatment of zoonotic cutaneous leishmaniasis under basic health care conditonsCHAHED, M. K; BEN SALAH, A; LOUZIR, H et al.Archives de l'Institut Pasteur de Tunis. 1999, Vol 76, Num 1-4, pp 13-18, issn 0020-2509Article

GLUCANTIME EFFICACY IN THE TREATMENT OF ZOONOTIC CUTANEOUS LEISHMANIASISPOURMOHAMMADI, B; MOTAZEDIAN, M. H; HANDJANI, F et al.Southeast Asian journal of tropical medicine and public health. 2011, Vol 42, Num 3, pp 502-508, issn 0125-1562, 7 p.Article

Les effets indésirables du Glucantime@ par voie générale, dans le traitement de la leishmaniose cutanée: A propos de 15 cas = Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 casesNADIA EZZINE SEBAI; MRABET, Nozha; KHALED, Aida et al.Tunisie médicale. 2010, Vol 88, Num 1, pp 9-11, issn 0041-4131, 3 p.Article

Short report : Efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasisSOTO, J; TOLEDO, J; VEGA, J et al.The American journal of tropical medicine and hygiene. 2005, Vol 72, Num 4, pp 421-422, issn 0002-9637, 2 p.Article

Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central IranMOHAMMADZADEH, Mahmoud; BEHNAZ, Fatemah; GOLSHAN, Zahra et al.Journal of infection and public health (Print). 2013, Vol 6, Num 2, pp 120-124, issn 1876-0341, 5 p.Article

Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasisCORDOBA, S; GANDOLFO CANO, M; AGUADO, M et al.Allergy (Copenhagen). 2012, Vol 67, Num 12, pp 1609-1611, issn 0105-4538, 3 p.Article

Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gunMANSOUR NASSIRI KASHANI; SADR, Bardia; MOHAMMAD ALI NILFOROUSHZADEH et al.International journal of dermatology. 2010, Vol 49, Num 9, pp 1034-1037, issn 0011-9059, 4 p.Article

Efficacy of Cryotherapy versus Intralesional Meglumine Antimoniate (Glucantime) for Treatment of Cutaneous Leishmaniasis in ChildrenLAYEGH, Pouran; PEZESHKPOOR, Fakhrozaman; AMIR HOSSEIN SORURI et al.The American journal of tropical medicine and hygiene. 2009, Vol 80, Num 2, pp 172-175, issn 0002-9637, 4 p.Article

Glibenclamide modulates glucantime activity and disposition in Leishmania majorPADRON-NIEVES, Maritza; DIAZ, Emilia; MACHUCA, Claudia et al.Experimental parasitology. 2009, Vol 121, Num 4, pp 331-337, issn 0014-4894, 7 p.Article

Role of Imiquimod and Parenteral Meglumine Antimoniate in the Initial Treatment of Cutaneous LeishmaniasisAREVALO, Iracema; TULLIANO, Gianfranco; QUISPE, Ana et al.Clinical infectious diseases. 2007, Vol 44, Num 12, pp 1549-1554, issn 1058-4838, 6 p.Article

Short Report: Intralesional Meglumine Antimoniate for Treatment of Cutaneous Leishmaniasis Patients with Contraindication to Systemic Therapy from Rio de Janeiro (2000 to 2006)DE CAMARGO FERREIRA E VASCONCELLOS, Erica; PIMENTEL, Maria Inês Fernandes; VALETE-ROSALINO, Claudia Maria et al.The American journal of tropical medicine and hygiene. 2012, Vol 87, Num 2, pp 257-260, issn 0002-9637, 4 p.Article

Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasisFIRDOUS, Rukhsana; YASINZAI, Masoom; RANJA, Khalid et al.International journal of dermatology. 2009, Vol 48, Num 7, pp 758-762, issn 0011-9059, 5 p.Article

Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniateSADEGHIAN, G; NILFROUSHZADEH, M. A; IRAJI, F et al.Clinical and experimental dermatology (Print). 2007, Vol 32, Num 4, pp 371-374, issn 0307-6938, 4 p.Article

Selective determination of Sb(III) in drugs by flow injection hydride generation aasDE MORAES FLORES, Erico Marlon; PAULA, Favero Reisdorfer; BARCELLOS DA SILVA, Fabiana Ernestina et al.Atomic spectroscopy. 2003, Vol 24, Num 1, pp 15-21, issn 0195-5373, 7 p.Article

Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasisESFANDIARPOUR, Iraj; ALAVI, Afsaneh.International journal of dermatology. 2002, Vol 41, Num 8, pp 521-524, issn 0011-9059, 4 p.Article

Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasisBERHE, N; ABRAHAM, Y; HAILU, A et al.East African medical journal. 2001, Vol 78, Num 11, pp 608-610, issn 0012-835XArticle

Toxicité cardiaque de l'antimoniate de méglumine (Glucantime®). À propos d'une observation = Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime®). A case reportMATOUSSI, N; AMEUR, H. B; AMOR, S. B et al.Médecine et maladies infectieuses. Supplément. 2007, Vol 37, Num 3, issn 1166-8237, S257-S259Article

Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinolMOMENI, Ali Z; AMINJAVAHERI, Malihalsadat.EJD. European journal of dermatology. 2003, Vol 13, Num 1, pp 40-43, issn 1167-1122, 4 p.Article